

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED

銘源醫療發展有限公司*

(Incorporated in Bermuda with limited liability)

(Stock code: 0233)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance.

Reference is made to the two announcements of the Company respectively dated 18 May 2016 (“**18 May Announcement**”) and 19 May 2016 (“**19 May Announcement**”) (collectively called “**the Two Announcements**”).

When the Two Announcements were made, the Company was still run by the old board of directors (“**Old Board**”) under the stewardship of Mr. Yao Yuan, the former chairman and executive director. By an announcement dated 20 May 2016, shareholders were informed that a new board of directors (“**New Board**”) was constituted on 20 May 2016 and Mr. Lam Ping Cheung (“**Mr. Lam**”) was appointed as chairman of the New Board.

All members of the New Board met on 8 June 2016, it was unanimously resolved, with Mr. Lam in abstention from voting, to make the announcement herein in relation to the matters raised in the Two Announcements.

** For identification purpose only*

In the 18 May Announcement, it was announced that the Old Board received a letter from Mr. Zhao Chao (“**Mr. Zhao**”), a former director of the Company, on 16 May 2016 (“**the Letter**”) and it was further said that Mr. Zhao was interviewed by a director appointed by the Old Board in a meeting held on 17 May 2016. Members of the New Board had asked staff members of the Company to run a full search at the Company’s registered principal place of business in Hong Kong who reported that no record was found to suggest that the Letter was received by the Old Board and that there was no minutes of the Old Board recording the alleged appointment of a director to attend the meeting with Mr. Zhao on 17 May 2016. In fact, staff member of the Company who was responsible to receive and record mails delivered to the Company had confirmed that no letter similar to the Letter was received by the Company on 16 May 2016.

Members of the New Board was provided with a letter from Mr. Lam’s solicitors Lam & Co. dated 19 May 2016 to the Securities and Futures Commission enclosing therein a print-out copy of the entire WeChat messages Mr. Lam exchanged with Mr. Zhao from 2122 hours on 18 May 2016 to 0003 hours on 19 May 2016.

In the Wechat messages, Mr. Zhao unequivocally denied that he had sent the Letter and that he had met with a director of the Company.

By Order of the Board
Mingyuan Medicare Development Company Limited
LAM Ping Cheung
Chairman

Hong Kong, 8 June 2016

As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors; (ii) Ms. Lam Yan Fong Flora as non-executive Director; and (iii) Ms. Chan Mee Sze, Ms. Hui Wai Man Shirley, Mr. Lam Suk Ping and Mr. Wong Anthony Chi-ho as independent non-executive Directors.

The Directors jointly and severely accept full responsibility for the accuracy of information contained in this announcement.